Axichem Q2’21: Getting Ready to Execute Its Commercialisation Strategy - Redeye
Redeye comments on aXichem’s Q2’21 report. The report did not include any major surprises, but we believe that the company has an interesting period ahead as it is ready to enter the commercial phase.
ANNONS
Redeye comments on aXichem’s Q2’21 report. The report did not include any major surprises, but we believe that the company has an interesting period ahead as it is ready to enter the commercial phase.